Answers are grounded in this paper and cite their sources.
Although immune checkpoint inhibitors (ICIs) combined with angiogenesis inhibitors (AGIs) has become increasingly used for cancers, the impact of combination therapy on immune-related adverse events (irAEs) in real-world settings has not been well elucidated to date.
No takes yet. Share an insight, caveat, or question.
Ren et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: